Department of Pediatrics

Advanced Immunotechnologies and Vaccine Formulations

Master
Heading

About the Lab

Content

The Laboratory for Advanced Immunotechnologies and Formulation aims to explore and advance vaccine technologies to develop novel and improved vaccine solutions.

Media Component
parasitic stage of protozoan Trypanosoma cruzi
Content

"Amastigote" usually refers to the stage in which Trypanosoma cruzi replicates in mammalian host cells. In this image, taken by confocal microscopy, amastigotes are seen in parasitophorous vacuoles around the nucleus. By using fluorescent dyes and a fluorescent antibody, we can observe the cell nucleus (blue, DAPI), actin filaments (white, phalloidin conjugate), and heat shock protein 40 (DnaJ), one of our vaccine candidates (magenta, antibody conjugate). 

Heading

Research Projects

Content

Vaccine Formulation

The Formulation Unit of our team oversees vaccine formulations at the Texas Children's Center for Vaccine Development. We guide members and collaborators in selecting vaccine adjuvants, excipients and development methods. Within our lab, we conduct formulation studies to verify the stability, safety and effectiveness of vaccine formulations before moving to animal models and clinical trials. Vaccine formulations for in vivo studies strictly adhere to stringent guidelines and standards to ensure quality and safety.

As projects progress through the Vaccine Centers development pipeline, we closely collaborate with the Quality Control and Quality Assurance Units. We support Regulated Activities by preparing the necessary documentation and executing regulated protocols.

Highlighted projects:

  • Chagas Vaccine Initiative
    Main Goal: The overall goal of the project is to advance the first therapeutic Chagas disease vaccine prototype through a First-in-Human Phase 1 clinical trial.
  • SARS-CoV Vaccine Development
    Main Goal: To support the development of a Pan-Sarbeco SARS-CoV vaccine

Advanced Immunotechnologies

Beyond formulation, our laboratory serves as a vaccine innovation hub for cutting-edge research and development across multiple domains to improve vaccines and immunotherapeutics.

Highlighted projects:

  • Immunopeptidomics of Chagas disease
    Main Goal: The discovery and analysis of immune-related peptides, elucidating their role in immune responses and aiding in vaccine design for Chagas disease.
  • Discovery and production of variant-specific Coronavirus mAbs  
    Main goal: Discovery and distribution of monoclonal antibodies for therapeutic, diagnostic, and research purposes.
  • RNA Vaccine Research
    Main Goal: Pioneering RNA-based technologies, exploring their potential for vaccine development and therapeutic interventions.
    • Passive Immunization of Foals with mRNA-Abs against Rhodococcus equi (USDA)
    • Develop and evaluate mRNA-vaccine to protect foals against Rhodococcus equi. (Grayson Jockey Club Research Foundation)
    • Leveraging intracellular protein trafficking to develop mRNA vaccines against hookworm and Schistosomiasis
  • Cell-based Vaccine Evaluations
    Main goal: Utilizing advanced in vitro assays and models to evaluate the potency and safety of pan coronavirus vaccine candidates, paving the way for impactful advancements in immunization strategies.
  • Delivery Technologies
    Main goal:  Evaluating innovative methods to formulate and deliver vaccines more effectively. 
Heading

Laboratory Members

People
First Name
Jeroen
Last Name
Pollet
Honorific Title
Ph.D.
Assistant Professor
First Name
Yi-Lin
Last Name
Chen
Postdoctoral Associate
First Name
Athos
Middle Name
Silva
Last Name
de Oliveira
Postdoctoral Associate
First Name
Syamala
Middle Name
Rani
Last Name
Thimmiraju
Postdoctoral Associate
First Name
Leroy
Last Name
Versteeg
mRNA vaccines against Neglected Tropical Diseases
First Name
Rakesh
Last Name
Adhikari
Research Asst I
Heading

Recent Publications